Mega IgG2000 Powder
PyloGuard
Clinical studies show PyloGuard™ supports managing H. pylori levels, particularly when used with antibiotics. It contains patented Lactobacillus reuteri DSM17648, which can attract specific organisms in the intestine and support their removal via the digestive tract. This particular strain of L. reuteri maintains H. pylori levels already within the normal range and supports overall digestive health.
How to buy?
A valid Practitioner account is required for direct purchases from our website. Let’s get you registered!
At a glance
Clinical studies show PyloGuard™ supports managing H. pylori levels, particularly when used with antibiotics. It contains patented Lactobacillus reuteri DSM17648, which can attract specific organisms in the intestine and support their removal via the digestive tract. This particular strain of L. reuteri maintains H. pylori levels already within the normal range and supports overall digestive health.
Key Benefits:
- Supports bacteria levels in the stomach
- Promotes the body’s process of elimination
- Supports the microbiome
- Maintains H pylori levels already within the normal range
Key Features:
- Lactobacillus reuteri DSM17648 culture containing ≥ 1 x1011 inactivated cells/gram
- Produced in a low-temperature fermentation & drying process to avoid denaturing
- Stable under the gastric conditions
- Doesn’t disturb the gut microbial balance
- Formulated in a free-flowing, spray-dried powder format
- Stable at room temperature
- Backed by in vitro and in vivo scientific research
- Safe for long-term daily use (QPS, MIC, GRAS)
- Produced and tested to exceed the most stringent EU quality standards (ISO)
- Free from GMO, lactose, and fructose
What is Helicobacter Pylori?
Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium native to the human gastrointestinal (GI) tract. It has an affinity for the acidic environment of the gastric mucosa. Estimates say that up to 50% of the world’s population carries H. pylori in their GI tracts. H. pylori is spread through direct contact with individuals or household pets through saliva, feces, or contaminated food or water.
Humanity’s relationship with H. pylori is ambiguous. H. pylori can have a commensal or symbiotic relationship with its human host.
H. pylori colonizes and multiplies in the duodenum and gastric mucosa, secreting urease, the enzyme that converts urea to ammonia. Alkaline ammonia buffers the naturally low pH of the stomach, providing the optimal environment for H. pylori to live.
Disruption of the microbiome can cause occasional:
- Nausea
- Heartburn
- Loss of appetite
- Dyspepsia
Dosing Instructions
Ages 9+: One capsule per day, or as directed by a healthcare practitioner. Children under the age of 9, please consult with your healthcare practitioner.
Immune Support Studies:
|
Form/Duration |
Study Details and Results |
Reference |
|---|---|---|
|
Pylopass® (PyloGuard™) 28 days and 56 days |
Placebo-controlled trial 103 participants, children 9-17 years Supported ammonia levels in Pylopass® (PyloGuard™) group Pylopass® (PyloGuard™) group reported higher rate of abdominal relief and reduced incidence of diarrhea |
DOI: 10.15406/ghoa.2020.11.00407 |
|
Pylopass® (PyloGuard™) 2 weeks |
Pilot study 27 participants DSM17648 co-aggregates with human strain of H. pylori without aggregating with any other commensal bacteria. Supplementation supported levels of H. pylori. |
DOI: 10.1007/s12602-014-9181-3 |
|
Pylopass® (PyloGuard™) 4 weeks |
Placebo-controlled, single-blind study 24 participants Supported H.pylori levels and improvement of abdominal discomfort |
DOI: 10.1186/s40795-018-0257-4 |
Immune Support Studies Continued:
|
Form/ Duration |
Study Details and Results |
References |
|
Pylopass® (PyloGuard™) 2 weeks |
Placebo controlled study 22 participants Supported H. pylori levels Effect still observed 6 months after end of supplementation |
DOI: 10.3390/nu5083062 |
|
Pylopass® (PyloGuard™) 4 weeks |
Randomized, double blind, placebo-controlled clinical study 200 participants Significant improvement of side effects compared to placebo group Promoted abundance of Fusicatenibacter, Subdoligranulum, and Faecalibacterium Mean GSRS score decreased significantly in the LR group as compared with the placebo group |
DOI: doi.org/10.1111/hel.12856 |
|
Pylopass® (PyloGuard™) 2 weeks |
90 participants Prospective and interventional randomized, double-center study. 86% eradication rate in Pylopass® (PyloGuard™) group. 20% higher eradication rate compared to standard therapy group. Significant reduction in symptoms compared to standard therapy group. |
DOI: 10.9734/JPRI/2021/v33i52B33611 |
